Kiniksa Pharmaceuticals, Ltd. (KNSA) Stock Analysis

Why this analysis is different

• A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Kiniksa Pharmaceuticals, Ltd. (KNSA) Healthcare & Pipeline Overview

Kiniksa Pharmaceuticals, Ltd. is a biopharmaceutical company specializing in the discovery and commercialization of therapies for debilitating diseases with unmet needs, primarily focusing on inflammatory and autoimmune conditions. Their lead product, ARCALYST, addresses recurrent pericarditis, positioning them in a niche cardiovascular market with potential for further pipeline expansion.

What Is the Investment Thesis for KNSA?

Kiniksa Pharmaceuticals, Ltd. presents a compelling investment thesis based on its established product, ARCALYST, and a promising pipeline of therapeutic candidates. ARCALYST's success in treating recurrent pericarditis provides a solid revenue foundation, evidenced by the company's 9.7% profit margin and 54.6% gross margin. The ongoing development of Vixarelimab for prurigo nodularis and KPL-404 targeting B-cell maturation represents significant growth catalysts, addressing markets with substantial unmet needs. However, potential risks include clinical trial outcomes, regulatory hurdles, and competition from established pharmaceutical companies. With a beta of 0.06, KNSA exhibits low volatility relative to the market, potentially appealing to risk-averse investors. The company's P/E ratio of 63.6 suggests a premium valuation, reflecting investor expectations for future growth.

Based on FMP financials and quantitative analysis

KNSA Key Highlights

Market capitalization of $5.98B, reflecting investor confidence in Kiniksa's pipeline and commercial prospects.

• Profit margin of 9.7%, indicating efficient operations and successful commercialization of ARCALYST.
• Gross margin of 54.6%, showcasing strong pricing power and cost management in the biopharmaceutical sector.
• Beta of 0.06, suggesting low volatility compared to the overall market, potentially attractive to risk-averse investors.
• ARCALYST, an approved product for recurrent pericarditis, provides a stable revenue stream and validates Kiniksa's drug development capabilities.

Who Are KNSA's Competitors?

KNSA is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are KNSA's Key Strengths?

Approved product (ARCALYST) generating revenue.

• Promising pipeline of therapeutic candidates.
• Expertise in inflammatory and autoimmune diseases.
• Strong intellectual property protection.

What Are KNSA's Weaknesses?

Reliance on ARCALYST for current revenue.

• Clinical trial risks associated with pipeline development.
• Competition from larger pharmaceutical companies.
• Regulatory hurdles in drug approval process.

What Could Drive KNSA Stock Higher?

Clinical trial results for Vixarelimab in prurigo nodularis.

• Regulatory submissions for pipeline candidates.
• Expansion of ARCALYST's market reach.
• Development of new therapeutic candidates.
• Strategic partnerships and collaborations.

What Are the Key Risks for KNSA?

Inconsistent delivery — missed Wall Street EPS estimates in 4 of the last 8 reported quarters.

• Rich valuation — a P/E of 63.6 runs well above the Healthcare sector’s ~23x, leaving little room for a miss.
• Unfavorable clinical trial outcomes.
• Regulatory delays or rejections.
• Competition from established therapies.
• Intellectual property challenges.
• Market access and reimbursement issues.

What Are the Growth Opportunities for KNSA?

• Expansion of ARCALYST's Indications: Kiniksa has the opportunity to expand the approved uses of ARCALYST beyond recurrent pericarditis. Exploring its efficacy in other IL-1 mediated diseases could significantly increase its market potential. The market for IL-1 inhibitors is projected to grow as research uncovers new applications. Successfully expanding ARCALYST's label could provide a substantial revenue boost for Kiniksa.
• Advancement of Vixarelimab for Prurigo Nodularis: Vixarelimab, currently in Phase 2a clinical trial for prurigo nodularis, represents a significant growth opportunity. Prurigo nodularis is a chronic inflammatory skin condition with limited treatment options, creating a substantial unmet need. Positive clinical trial results and subsequent regulatory approval could position Vixarelimab as a key therapy in this market, driving significant revenue growth for Kiniksa.
• Development of KPL-404 for Autoimmune Diseases: KPL-404, a monoclonal antibody inhibitor of the CD40-CD154 interaction, targets B-cell maturation and immune response. This mechanism of action has broad potential applications in various autoimmune diseases. Advancing KPL-404 through clinical trials and securing regulatory approval could open up multiple therapeutic avenues for Kiniksa, diversifying its product portfolio and revenue streams.
• Strategic Partnerships and Acquisitions: Kiniksa can pursue strategic partnerships and acquisitions to expand its pipeline and access new technologies. Collaborating with other biotechnology companies or acquiring promising therapeutic candidates could accelerate Kiniksa's growth and enhance its competitive position. These partnerships could provide access to novel drug targets, delivery systems, or therapeutic modalities.
• Geographic Expansion: Kiniksa can expand its commercial operations into new geographic markets. While currently focused on global markets, targeting specific regions with high unmet medical needs and favorable regulatory environments could drive revenue growth. This expansion could involve establishing local sales and marketing teams or partnering with regional distributors.

What Are KNSA's Competitive Advantages?

• Proprietary drug candidates with patent protection.
• Established expertise in developing therapies for inflammatory diseases.
• Commercial infrastructure for marketing and selling ARCALYST.
• Strong relationships with key opinion leaders in relevant therapeutic areas.

What Does KNSA Do?

Kiniksa Pharmaceuticals, Ltd. is a biopharmaceutical company dedicated to discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs. Incorporated in 2015 and based in Hamilton, Bermuda, Kiniksa has rapidly evolved into a player in the biotechnology sector, focusing on inflammatory and autoimmune conditions. The company's lead product, ARCALYST (rilonacept), is an interleukin-1alpha and interleukin-1beta trap indicated for recurrent pericarditis and other IL-1 mediated diseases. Beyond ARCALYST, Kiniksa's pipeline includes Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis, Vixarelimab, a monoclonal antibody in Phase 2a clinical trial for prurigo nodularis, and KPL-404, a monoclonal antibody inhibitor of the CD40-CD154 interaction, targeting B-cell maturation and immune response. Kiniksa's strategy involves identifying promising therapeutic candidates, advancing them through clinical development, and ultimately commercializing them to address critical unmet needs in various disease areas. The company operates globally, seeking to bring innovative therapies to patients worldwide.

What Products and Services Does KNSA Offer?

• Discovers and develops therapeutic medicines.
• Acquires promising drug candidates.
• Commercializes therapies for debilitating diseases.
• Focuses on unmet medical needs worldwide.
• Develops treatments for inflammatory and autoimmune conditions.
• Markets ARCALYST for recurrent pericarditis.
• Advances Mavrilimumab, Vixarelimab and KPL-404 through clinical trials.

How Does KNSA Make Money?

• Develops and commercializes proprietary pharmaceutical products.
• Generates revenue through sales of ARCALYST.
• Out-licenses or partners for development and commercialization of certain assets.
• Invests in research and development to expand its pipeline.

What Industry Does KNSA Operate In?

Kiniksa Pharmaceuticals, Ltd. operates within the biotechnology industry, a sector characterized by intense research and development, high regulatory scrutiny, and significant growth potential. The market for biopharmaceutical products is expanding, driven by an aging global population and increasing prevalence of chronic diseases. Kiniksa's focus on inflammatory and autoimmune conditions aligns with key market trends, as these areas represent significant unmet medical needs. Competitors include companies like APLS: Apellis Pharmaceuticals, Inc. and FOLD: Amicus Therapeutics, Inc., which are also developing therapies for rare and inflammatory diseases. The biotechnology industry is subject to rapid innovation and evolving regulatory landscapes, requiring companies to adapt and innovate continuously.

Who Are KNSA's Key Customers?

• Patients suffering from recurrent pericarditis.
• Patients with giant cell arteritis.
• Patients with prurigo nodularis.
• Healthcare providers prescribing Kiniksa's therapies.

Kiniksa Pharmaceuticals, Ltd. (KNSA) Valuation Context

Valued at $5.98B, KNSA is classified as a mid-cap stock. Relative to its peer group, KNSA's quantitative score of 44/100 is below the peer average of 65/100.

KNSA Revenue & Earnings Trend

In Q2 2026, KNSA generated $243.6M in top-line revenue, marking a sequential increase of 13.7%. The company recorded net income of $25.4M, with diluted EPS of $0.30. Revenue has increased across the last three reported quarters, suggesting sustained momentum for this mid-cap Healthcare company. Across the four most recent quarters, KNSA averaged $0.24 in diluted EPS.

Company Profile

Kiniksa Pharmaceuticals, Ltd. operates in the Medical - Pharmaceuticals industry within the Healthcare sector. It is headquartered in London, GB. The company is led by CEO Sanj K. Patel. KNSA has traded publicly since 2018.

Return on equity for Kiniksa Pharmaceuticals, Ltd. stands at 13.3%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 8.9%, showing how much profit it generates from its asset base. KNSA trades at a trailing price-to-earnings ratio of 63.55, above the Healthcare sector average of ~23x. Its free cash flow yield is 3.6%, a gauge of the cash the business throws off relative to its market value. A current ratio of 3.79 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 1.6%, the inverse of the P/E and a quick read on earnings relative to price.

Kiniksa Pharmaceuticals, Ltd.'s Piotroski F-Score is 6/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 16.63 places it in the safe zone, indicating low near-term bankruptcy risk.

Kiniksa Pharmaceuticals, Ltd. has missed Wall Street's EPS estimate in 4 of its last 8 reported quarters — a mixed record worth weighing. Reported results have landed about 38.3% below estimates on average.

Wall Street analysts project Kiniksa Pharmaceuticals, Ltd. revenue of about $993.6M for fiscal 2026, with EPS near $1.39. The estimate reflects 6 contributing analysts.

KNSA Financials

KNSA Latest News

KNSA Analyst Consensus

KNSA MoonshotScore

Latest Kiniksa Pharmaceuticals, Ltd. Analysis

Kiniksa Pharmaceuticals, Ltd. Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources